OBJECTIVES: To compare  cost of rituximab both Intravascular and subcutaneous for the treatment of NHL in patients within the social security and retiree segment And leaving in rural areas of ARGENTINA. METHODS: Insurance given by two main sectors were analysed. IOMA  covers 157.741 beneficiaries while PAMI  covers 215.118 . 1st line and 2nd line full treatments were calculated. As RTX cost is equivalent between formulations, we calculated the modules of the treatment including medical fee, materials etc. taking into account the IOMA value of USD 140.20 and PAMI one of USD 127.12 and the time of treatment in minutes we estimate the savings with the SC formulation. RESULTS: IOMA Cost taking into account the consumption of time is around   USD 1.190, 78 for the first line treatment and USD 899, 66 for the second line; meanwhile PAMI cost are around USD 1.079, 66 for the first line and USD 815, 70 for the second one. Sc first line is  USD 192, 98 per minute and USD 73, 61 per minute the second line for IOMA and PAMI SC USD 174, 97 per minute for the first one and USD 66, 74 per minute for the second one. Ratio between IV RTX cost and application is for IOMA 1 L  19.62 % and 14, 82 %  2 L; for PAMI the ratio for IV first line is  17, 78 % and for 2L 13, 44 %. SC represents  IOMA 1 L 3, 18 % and 2L 1, 21 %, For PAMI is 2, 88 % 1L and  1, 10 % 2L. El ahorro nominal por tratamiento es de USD 997, 80 para IOMA y de USD 904, 69  PAMI. CONCLUSIONS: nominal saving are around USD 997 for IOMA and 904, 69 for PAMI for treatment. IV takes 5,30 as average meanwhile SC just 27 minutes that could improve patients quality of life.